NEW YORK (GenomeWeb News) – Abbott received CE Marking in the European Union for its RealTime mS9 Colorectal cancer test, a non-invasive DNA assay that detects the methylated form of Septin 9. The assay, which runs on Abbott's m2000 PCR-based molecular diagnostic system, can be used by physicians to determine if a patient should be referred for colonoscopy. The test is not available for sale in the US, the firm noted.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.